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OBJECTIVES: High-dose atorvastatin crystalline has been shown to reduce the risk 
of recurrent stroke among patients with a recent stroke/TIA. It was found to be a 
cost-effective treatment strategy in many countries; however, there is no data available 
in Thailand. This study examined the cost-effectiveness of atorvastatin crystalline 
80 mg/day compared to usual treatment in prevention of recurrent stroke in Thailand. 
METHODS: A discrete event simulation was used to project long-term results of 
atorvastatin crystalline reported in the Stroke Prevention by Aggressive Reduction in 
Cholesterol Levels (SPARCL) trial. A clinical course following a stroke or TIA was 
simulated based on the risks of stroke and cardiovascular events observed from the 
trial adjusted by baseline demographics and risk factors of Thai patients. Costs and 
resource use were obtained from Chulalongkorn Stroke Database, life expectancy 
from Saskatchewan Health Database, and utility weights from a literature. Costs, 
survival, and quality-adjusted life-years (QALYs) were estimated over lifetime from a 
health-care provider perspective; discounted 3% annually. RESULTS: Compared to 
usual care, using atorvastatin crystalline resulted in a decrease in numbers of stroke, 
TIA, MI, angina and other cardiovascular events which led to an average gain of 0.28 
QALYs and 0.27 survival years per patient. A net additional cost of atorvastatin 
crystalline resulting from higher drug costs and reduction in direct medical costs was 
182,910 baht/patient, or 483,800 baht/QALY (US $14,229) gained. Subgroup analy-
ses indicated that lower ICERs (396,000–464,000 baht/QALY or US$11,647–
US$12,470) have been shown in high risks patients (e.g., older age, history of stroke/
TIA, diabetes, hypertension). CONCLUSIONS: For patients with prior stroke/TIA, 
using atorvastatin crystalline comparing to current post-stroke care is clinically effec-
tive in Thai stroke patients. ICER is slightly in excess of three times of GDP/capita 
(US$11,920) as the threshold recommended by WHO, however, it still can be consid-
ered economically tolerable as a cost-effective use was found in speciﬁ c patient groups. 
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OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban against enoxaparin 
for prevention of venous thromboembolism (VTE) after total hip (THR) and knee 
(TKR) replacement in China. METHODS: An economic model was developed, con-
sisting of three modules: prophylaxis, post-prophylaxis, and long-term complications. 
The ﬁ rst two modules were represented using a decision tree while the third module 
used a Markov process. Safety and efﬁ cacy data during prophylaxis were derived from 
a pooled analysis of Chinese patients enrolled in two phase III registration trials 
(RECORD 2 and 3). Utility outcomes and the probability of long-term events were 
based on systematic review and published data. Resource use related to VTE preven-
tion, treatment and complications was based on clinical guidelines, product labels, 
and interviews conducted in six Tier 3 hospitals in Beijing, Shanghai and Guangzhou 
City. Unit cost data were collected from the government pricing bureau presented in 
2009 CNY from the health-care system perspective. Costs and outcomes were dis-
counted at 3% per annum. Extensive one-way and probabilistic sensitivity analyses 
were undertaken. RESULTS: In the base case analyse, rivaroxaban was shown to be 
dominant compared with enoxaparin. Rivaroxaban was associated with 0.0065 addi-
tional QALYs per patient while saving an average of CNY 232 per patient over 5 
years. Probabilistic sensitivity analyses estimated that rivaroxaban is more effective 
and less expensive in 57.8% of all stochastic model runs. The probability of rivaroxa-
ban being cost-effective was 60% with a willingness-to-pay threshold of CNY 20,000 
per QALY and 80% with a threshold of CNY 100,000. CONCLUSIONS: Compared 
with enoxaparin in a pooled analysis of Chinese patients, rivaroxaban improved health 
outcomes and produced cost savings in VTE prevention after TKR and THR in China. 
Sensitivity analyses indicated the results of model are robust. 
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OBJECTIVES: To assess cost-effectiveness of blood pressure and/or cholesterol lower-
ing drugs for cardiovascular disease prevention. METHODS: Design: A Markov 
model using Generalized Cost-Effectiveness Analysis with “do-nothing” as a compara-
tor; health sector perspective on life time cost-effectiveness and 3% discounting for 
both cost and effects. Setting: Primary care, Thailand Target Population: Thai popula-
tion aged 30 years or above in 2004 classiﬁ ed by 10-year absolute risk of cardiovas-
cular disease. Intervention: Blood pressure and cholesterol lowering drugs. Outcome 
Measure: Average and incremental cost-effectiveness in Thai baht per disability 
adjusted life-year averted. RESULTS: Base-Case Analysis: The most cost-effective 
option for cardiovascular disease prevention in people with 10-year risks of 5% and 
greater was the polypill followed by combinations of three blood pressure drugs with 
or without a statin. Single generic drugs, except angiotensin reuptake blockers were 
also very cost-effective, but dominated by drug combinations due to greater health 
gain and shared costs. Sensitivity Analysis: All generic drugs except beta blockers and 
angiotensin reuptake blockers, and the above combinations were very cost-effective; 
the median cost effectiveness ratios for all of these drugs were below one times gross 
domestic product per capita in people with 10-year risks of 5% and greater. CON-
CLUSIONS: Primary cardiovascular disease prevention with a combination of generic 
drugs in Thailand is very cost-effective when the 10-year absolute risk is 5% or higher. 
PCV21
MODELING THE COST-EFFECTIVENESS OF CORONARY COMPUTED 
TOMOGRAPHY FOR PATIENTS WITH CHEST PAIN USING BOTH 
DIAGNOSTIC AND PROGNOSTIC INFORMATION
Priest VL1, Scuffham PA2, Marwick T3
1Grifﬁ th University, Brisbane, Queensland, Australia; 2Grifﬁ th University, Meadowbrook, 
Queensland, Australia; 3University of Queensland, Brisbane, Queensland, Australia
OBJECTIVES: Most Emergency Room (ER) presentations with chest pain are unre-
lated to coronary artery disease (CAD). Coronary computed tomography (CT) has 
been proposed to allow earlier exclusion and discharge of patients at low risk of CAD, 
resulting in cost-savings in the management of chest pain. Knowing the expected 
health outcomes, costs and cost-effectiveness of new diagnostic tests is important, but 
few comparative trials are undertaken and modeling is often required. Prognostic 
information links test results to long-term risks of events and mortality, and is the 
most relevant information for risk-stratiﬁ cation and predicting patient outcomes. 
However, head-to-head trials of diagnostic techniques are uncommon, and may be 
confounded by underlying patient characteristics and prevalence of disease in the trial 
population. In contrast, diagnostic accuracy information can be adapted to predict 
the expected occurrence of false diagnoses in a tested population by using epidemio-
logical formulas that incorporate the underlying disease prevalence rate. METHODS: 
A decision-analytic model was designed to compare CT with exercise-stress testing 
using echocardiography (ExE) or single-photon emitting computed tomography 
(SPECT) using the available diagnostic and prognostic evidence. Epidemiological 
formulas were used to determine the initial proportion of the population that tested 
positive and negative, and determined clinical management of patients who tested 
positive for CAD. Long-term outcomes were modeled using hard-event rates (myocar-
dial infarction and mortality) in clinical trials that report 12-month follow-up of 
patients tested with each diagnostic test. RESULTS: The results indicate CT may be 
associated with a higher rate of events in patients with an initial negative test, which 
would negate some of the cost-savings from faster initial diagnosis. The analysis is 
sensitive to the rate, and consequences, of misdiagnosis. CONCLUSIONS: More 
information on the prognosis of patients with an initial negative CT test is needed 
before this strategy is accepted to be cost-saving in the diagnosis of chest pain. 
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OBJECTIVES: Comparison of cost-effectiveness of rivaroxaban with dabigatran in 
prevention of venous thromboembolism (VTE) in patients after total hip replacement 
(THR) from payer perspective in Slovakia. METHODS: In a cost-utility model results 
of two large randomized controlled trials were used. Patients in both studies received 
35 days prophylaxis regimen: in RECORD 1 with rivaroxaban or enoxaparin and in 
RE-NOVATE with dabigatran or enoxaparin. Indirect comparison in metaanalysis 
showed that rivaroxaban reduced total VTE by 64% and symptomatic VTE by 82% 
versus dabigatran. Three parts of model represents prophylaxis, post-prophylaxis, and 
long-term complications. Data from RECORD 1 and RE-NOVATE trials are used for 
ﬁ rst part of the model. Published epidemiological and clinical data estimating the risk 
of further VTE events and post-thrombotic syndrome beyond the trial period were 
used in second and third part of the model. Published price lists (2010) were used for 
local cost data. Utilities related to VTE were derived from literature. Time horizon 
was set at 5 years and payers perspective was used. Quality-adjusted life-years (QALY) 
were chosen for effectiveness measurement and discount rate of 5% per year for costs 
and effects was applied according to valid guidelines for health economic evaluation 
in Slovakia. One-way and probabilistic sensitivity analyses were performed. RESULTS: 
Rivaroxaban showed cost-effectiveness versus dabigatran, with a small cost reduction 
of 0.46f and a QALY gain of 0.0016 per patient. In probabilistic analysis 84.3% of 
simulations were below 18,000f/QALY, which is ofﬁ cially published threshold for 
willingness to pay in Slovakia. CONCLUSIONS: Rivaroxaban is a cost-effective 
alternative to dabigatran for the prevention of VTE following THR in Slovakian 
setting. 
